# Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26
Canonical URL: https://biopharmsignal.com/news/MDXH/mdxhealth-to-present-fourth-quarter-and-full-year-2024-financial-results-and-cor-21e53bef
Ticker: MDXH
Company: MDxHealth
Source: MDxHealth
Published: 2025-02-12 21:00 EST
## Summary

Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025...

## Article Body
Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET

IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, February 26, 2025.

| Title: | Mdxhealth Presents Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call and Webcast |
| --- | --- |
| Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
| Date: | February 26, 2025 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call D ial-in Details: | United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064 |
| Conference ID: | 10196702 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1706814&tp_key=e01537d9e2 |

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
## Recent Company News
- 2026-07-24 20:59 EST — [Mdxhealth Announces Receipt of Nasdaq Notification Regarding  Minimum Market Value of Listed Securities Deficiency](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-market-valu-cf439d90) — Source: MDxHealth
- 2026-07-02 20:00 EST — [Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-d-bdf178d6) — Source: MDxHealth
- 2026-06-29 12:00 EST — [Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-peer-reviewed-publication-of-oxford-gps-prompt-study-in-euro-d931d4ac) — Source: MDxHealth
- 2026-05-13 20:00 EST — [Mdxhealth Reports Q1-2026 Results](https://biopharmsignal.com/news/MDXH/mdxhealth-reports-q1-2026-results-52a85fa2) — Source: MDxHealth
- 2026-04-30 20:00 EST — [Mdxhealth to Release First Quarter 2026 Financial Results on May 13](https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-first-quarter-2026-financial-results-on-may-13-70772180) — Source: MDxHealth
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)